Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
Date
2021Author
Rietschel, P.
Pouliot, J.
Lee, S.
Seebach, F.
Lowy, I.
Gullo, G.
Bondarenko, I.
Sezer, A.
Kilickap, S.
GÜMÜŞ, MAHMUT
ÖZGÜROĞLU, Mustafa
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Mcginniss, J.
Metadata
Show full item recordCollections
- Makale [92796]